10-Q · May 15, 2026
60 Degrees Pharmaceuticals (SXTP) reported a significant decline in revenue to $303,385 for Q4 2026, falling 43.5% compared to both the prior quarter and prior year. The company continues to face high operating losses…
Earnings analysis · 10-Q
SXTP earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include current-quarter income statement, balance sheet, cash-flow, or segment figures, so operating trends and EPS cannot be assessed from the filing excerpt. The key developments are…
Read full summary
The supplied 10-Q text does not include current-quarter income statement, balance sheet, cash-flow, or segment figures, so operating trends and EPS cannot be assessed from the filing excerpt. The key developments are persistent control deficiencies as of June 30, 2026, with 3 material weaknesses still unresolved despite a prior expectation of remediation in the first half of 2026. Nasdaq compliance remains a material concern because equity of approximately $2,614,185 was only $114,185 above the $2,500,000 minimum, while the company continues to incur losses and may need additional financing.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Equity remains above Nasdaq threshold
Stockholders’ equity attributable to the company was approximately $2,614,185 as of June 30, 2026, only modestly above Nasdaq’s $2,500,000 minimum equity requirement.
-
Additional financial reporting procedures
Management stated that it continues to evaluate its control environment and will perform additional analyses and procedures to support U.S. GAAP reporting until remediation is completed.
-
No reportable litigation events
There were no reportable litigation events during the quarter ended June 30, 2026.
What to watch
-
Material weaknesses remain unresolved
Management concluded that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 because of 3 identified material weaknesses: inadequate policy design, insufficient documentation, and access-control/segregation-of-duties deficiencies.
-
Remediation depends on financing
The company expected to remediate the 3 material weaknesses during the first half of 2026, but stated in this filing that remediation had not yet been completed and is largely dependent on securing additional financing.
-
Nasdaq equity compliance risk
Stockholders’ equity was approximately $2,614,185 as of June 30, 2026, versus Nasdaq’s $2,500,000 minimum; continued losses could push equity below the threshold and trigger delisting proceedings.
-
Potential future market-value rule
Nasdaq proposed a potential $5,000,000 minimum market value of listed securities requirement for Nasdaq Capital Market companies. The proposal was stayed and is not currently effective, but could be adopted or reinstated.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text. Management stated that remediation of material weaknesses will proceed as resources become available, with financing needed to fund implementation costs.
Earlier filings 4
10-K · March 30, 2026
60 Degrees Pharmaceuticals (60P / SXTP) is a small specialty pharma focused on tafenoquine (Arakoda) commercialization and follow-on clinical programs (babesiosis). Revenue more than doubled year-over-year in 2025 to…
10-Q · November 13, 2025
Q3 2025 showed a strong revenue pickup with product revenues of $437,602 (vs $135,293 in Q3 2024) but the company remains unprofitable and cash-consuming. Gross profit swung to a loss of $(100,088) and operating loss…
10-Q · August 13, 2025
Quarterly results show a meaningful operational improvement: Net revenue rose to $257,820 in Q2 2025 from $36,136 in Q2 2024, driven by research revenue, and loss from operations narrowed to $(1,604,828) from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.